SCPS 주가 차트
SCPS 수입
Scopus Biopharma Inc
$0
0%
$0
오늘 기준:May 12, 14:37:53 GMT-4
뒤로
Scopus Biopharma Inc (SCPS) 수입
최신 수익 결과: Q3 '21
보고됨: 2021-11-12
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
SCPS의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Scopus Biopharma Inc SCPS의 지난 분기 매출 실적은 어땠나요?
Scopus Biopharma Inc의 매출 추정치는 얼마인가요?
Scopus Biopharma Inc의 수익 품질 점수는 얼마인가요?
Scopus Biopharma Inc는 언제 수익을 보고하나요?
Scopus Biopharma Inc의 예상 수익은 얼마인가요?
Scopus Biopharma Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.0006
시가
$0.0004
일일 범위
$0.0004 - $0.0006
52주 범위
$0.0003 - $0.01
거래량
47.0K
평균 거래량
1.2K
배당수익률
--
EPS(TTM)
-0.32
시가총액
$25.2K
SCPS란 무엇인가요?
Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of therapeutics targeting diseases with unmet medical needs. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2020-12-16. The firm is developing therapeutics targeting serious diseases with significant unmet medical needs. Its lead development programs are CO-sTiRNA and MRI-1867. Its CO-sTiRNA is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. CO-sTiRNA is a dual-action STAT3 inhibitor. STAT3 is a gene that drives tumor cell growth and anti-tumor immune suppression. CO-sTiRNA also stimulates TLR9 receptors to activate the body’s immune defense to recognize and kill cancer cells. The company is also developing MRI-1867 for the treatment of SSc. SSc is a chronic, systemic autoimmune disease. MRI-1867, is a peripherally-restricted, dual-action cannabinoid-1, or CB1, receptor inverse agonist and inhibitor of inducible nitric oxide synthase, or iNOS.
